logo

For the Inventor, By the Inventor

Danbury, CT, United States of America

Mannkind Corporation


USPTO Granted Patents = 286

% Expired Patents = 18.2



Forward Citations = 4,729

Loading Chart...
Loading Chart...

153 inventors (with patents filed for the assignee):

goldMedal Chad C Smutney (65 out of 76 patents)

silverMedal Benoit Adamo (60 out of 90 patents)

bronzeMedal P Spencer Kinsey (57 out of 72 patents)

4.  John M Polidoro (38 out of 63 patents)

5.  Marshall L Grant (34 out of 34 patents)

6.  Carl R Sahi (29 out of 48 patents)

7.  Solomon S Steiner (26 out of 59 patents)

8.  Kelly Sullivan Kraft (22 out of 27 patents)

9.  Trent A Poole (22 out of 38 patents)

10.  John J Freeman (21 out of 34 patents)

11.  Dennis Overfield (21 out of 21 patents)

12.  Bryan R Wilson (20 out of 25 patents)

13.  Scott McLean (19 out of 88 patents)

14.  Andrea Leone-Bay (18 out of 118 patents)

15.  Brendan F Laurenzi (18 out of 19 patents)


Core Competencies:
Dry Powder Inhaler
Fluid Delivery Device
Diketopiperazine
Diabetes Treatment
Pharmaceutical Composition
Cryogranulation
Ultrarapid Acting Insulin
Microparticles
Drug Formulation
Prefilled Cartridge
Blister Package

286 patents:

1. 12734291 - Time delay mechanism for a hydraulic drug delivery device (2026-09-15),
2. 12728216 - Apparatus, system and method for detecting and monitoring inhalations (2026-09-08),
3. 12679811 - Microcrystalline diketopiperazine compositions and methods (2026-07-14),
4. 12673153 - Fluid delivery device (2026-07-07),
5. 12582784 - Dry powder inhalation system (2026-03-24),
6. 12576093 - Pharmaceutical composition for subcutaneous administration (2026-03-17),
7. 12576009 - Adapter for a fluid transfer device (2026-03-17),
8. 12521492 - Communication accessory for a drug delivery device (2026-01-13),
9. 12508376 - Dry powder inhaler (2025-12-30),
10. 12465681 - Cartridge insertion mechanism for a fluid delivery device (2025-11-11),
11. 12459903 - Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine (2025-11-04),
12. 12453702 - Apparatus and method for cryogranulating a pharmaceutical composition (2025-10-28),
13. 12447293 - Dry powder inhaler and system for drug delivery (2025-10-21),
14. 12440620 - Moving basal engine for a fluid delivery device (2025-10-14),
15. 12433889 - Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them (2025-10-07),
Company Overview
Mannkind Corporation, based in Danbury, Connecticut, specializes in innovative drug delivery systems, focusing on advanced inhalation technologies. The company is known for its development of dry powder inhalers and fluid delivery devices, particularly for diabetes treatment. Mannkind's core technologies include ultrarapid acting insulin formulations and microparticle systems, utilizing methods such as cryogranulation and diketopiperazine chemistry. Their commitment to enhancing patient care through effective pharmaceutical compositions positions them as a leader in the biopharmaceutical sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Mannkind Corporation USPTO Patent Assignee Logo
286 Patents

#4 in Danbury, CT

#44 in Connecticut

#1,534 in US

#3,102 in the World

Danbury, CT (US)
Danbury, CT, United States of America

Mannkind Corporation

Forward Citations = 4,729

153 inventors:

goldMedal Chad C Smutney (65 out of 76 patents)

silverMedal Benoit Adamo (60 out of 90 patents)

bronzeMedal P Spencer Kinsey (57 out of 72 patents)

4.  John M Polidoro (38 out of 63 patents)

5.  Marshall L Grant (34 out of 34 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mannkind Corporation. Retrieved from https://idiyas.com/company/mannkind

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…